ASX Health Stocks: Chimeric gets licence for CAR-T from U-Pen, Acrux gets nod from the FDA
Health & Biotech
Health & Biotech
Link copied to
ASX 200 health stocks index rose by 0.21% this morning, compared to the broader index which fell by 0.22%.
Chimeric Therapeutics (ASX:CHM) rose by 6% after obtaining the exclusive license to a novel CAR-T for solid tumours from the University of Pennsylvania, which will bring its novel CDH17 CAR-T cell therapy to more patients.
The novel therapy targets gastrointestinal tumors including colorectal cancer, pancreatic cancer and gastric cancer.
Meanwhile, the US FDA has approved Acrux (ASX:ACR)’s generic version of its EMLA Cream.
The submission was made by Acrux in 2019, and the approval today means that it can start manufacturing and marketing the generic drug.
The product is used on normal intact skin for local analgesia, on superficial minor surgery, and as a pre-treatment for infiltration anaesthesia.
Anteo signed a distribution agreement with Apacor for the sale of its EuGeni Reader platform and SARS-CoV-2 Antigen Rapid Diagnostic Test in the UK.
The company says the current Apacor sales team have many years’ experience operating in the UK market, particularly with government tenders.
The EuGini Reader is a compact device for rapid point-of-care testing and used in COVID-19 antigen rapid testing, with a saliva-based test currently in validation.
ILA, which is focused on mosquito diseases, closed the quarter with a cash position of $6.5m.
Highlights for the quarter include the securing of drug product manufacturing agreements, which shorten the timeline to ISLA-101 clinical trials.
This was the first earning release since the company’s ASX debut in April.
The medtech company closed the quarter with a $6.5 million cash as of 30 June. During the quarter, substantial progress was made on the registration of its cannabinoidd-based EMD-003, Emyria’s first lead product candidate to treat symptoms of anxiety, depression and stress.
The medicinal cannabis company reported a significant increase in its quarterly revenue to $623k, up from $183k in the previous quarter. Medicinal cannabis sales are now forecasted to reach $2m by the end of CY21.